Royal Bank of Canada Reaffirms Outperform Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report)'s stock had its "outperform" rating reissued by analysts at Royal Bank of Canada in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $11.00 price target on the biotechnology company's stock. Royal Bank of Canada's target price points to a potential upside of 52.35% from the stock's current price.

Other equities research analysts have also recently issued reports about the company. Needham & Company LLC restated a "buy" rating and set a $15.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Thursday, April 10th. JMP Securities reissued a "market outperform" rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Wedbush initiated coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 target price on the stock. Finally, Evercore ISI boosted their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $15.57.

BioCryst Pharmaceuticals Price Performance

BCRX stock traded down $0.18 during mid-day trading on Friday, reaching $7.22. The company had a trading volume of 1,642,802 shares, compared to its average volume of 2,797,924. The firm has a 50 day moving average of $7.91 and a 200 day moving average of $7.74. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $9.50. The company has a market capitalization of $1.51 billion, a PE ratio of -11.84 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. The firm's quarterly revenue was up 40.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.28 earnings per share. Analysts anticipate that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds have recently bought and sold shares of BCRX. Vanguard Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after purchasing an additional 1,583,826 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company's stock worth $36,776,000 after acquiring an additional 127,708 shares during the last quarter. Caligan Partners LP boosted its position in shares of BioCryst Pharmaceuticals by 16.0% during the 4th quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock worth $22,529,000 after purchasing an additional 412,347 shares during the period. Two Sigma Advisers LP increased its holdings in BioCryst Pharmaceuticals by 14.6% in the 4th quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company's stock valued at $18,799,000 after purchasing an additional 318,800 shares during the last quarter. Finally, Northern Trust Corp boosted its position in shares of BioCryst Pharmaceuticals by 7.7% during the fourth quarter. Northern Trust Corp now owns 2,004,911 shares of the biotechnology company's stock worth $15,077,000 after buying an additional 143,986 shares during the period. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.